Psyence Biomedical Ltd. Common Shares (PBM) Stock Price

PBMStock
$4.22−96.87%52W
Market Cap$16.10M
P/E13.08x
PEG Ratio0.36
Div yield—
Beta1.69

PBM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)33.15%
Price vs S&P 500 (4W)-33.95%
PEG Ratio0.36
VGM Score76.55
P/E Ratio (Annual)13.08x

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
PBMPsyence Biomedical Ltd. Common Shares
—AC———143.9%$4.22
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Psyence Biomedical Ltd. Common Shares

Psyence Biomedical Ltd is a biotechnology company developing psilocybin-based treatments for mental health conditions, including psychological trauma in palliative care. The company's product candidates are advancing through clinical trials to evaluate safety and efficacy. It operates a federally licensed cultivation facility in Southern Africa to produce natural psilocybin mushrooms for export and standardized pharmaceutical processing.